The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction

Sponsor
Rabin Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT02334839
Collaborator
(none)
150
1
12
12.5

Study Details

Study Description

Brief Summary

Preeclampsia toxemia (PET) is a pregnancy related complication that is usually expressed as new onset hypertension and proteinuria after 20 weeks of gestation. scarce data exists regarding the effectiveness of PAT plethysmography use in women with PET and whether adverse results are found compared to healthy gravidas. Thus, we aimed to assess endothelial function using PAT plethysmography in women with PET and compare their results to both healthy gravidas and those with only gestational hypertension.

.

Condition or Disease Intervention/Treatment Phase
  • Other: Observational only

Detailed Description

Preeclampsia toxemia (PET) is a pregnancy related complication that is usually expressed as new onset hypertension and proteinuria after 20 weeks of gestation. Although the exact pathophysiology is unclear, it's related to abnormal placentation and subsequent vascular pathology. Endothelial dysfunction was found to play a significant role in the risk of cardiovascular event in general. Moreover, few studies found a relation between endothelial dysfunction and PET. There are several methods for the assessment of endothelial function, with Peripheral Artery Tone (PAT) plethysmography being an emerging non-invasive promising technique. However, scarce data exists regarding the effectiveness of PAT plethysmography use in women with PET and whether adverse results are found compared to healthy gravidas.

Thus, we aimed to assess endothelial function using PAT plethysmography in women with PET and compare their results to both healthy gravidas and those with only gestational hypertension.

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction
Study Start Date :
Sep 1, 2014
Anticipated Primary Completion Date :
Sep 1, 2015
Anticipated Study Completion Date :
Sep 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Preeclampsia

women with diagnosed preeclampsia

Other: Observational only
Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.

gestational hypertension

women with diagnosed gestational hypertension without preeclampsia

Other: Observational only
Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.

healthy

women without gestational hypertension or preeclampsia

Other: Observational only
Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.

Outcome Measures

Primary Outcome Measures

  1. Reactive Hyperemia Index (RHI) [24 months]

    The difference in Reactive Hyperemia Index (RHI) as messureas using the ENDOPAT device between the study groups

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Maternal age 18-40 years old

  2. 27 and above weeks of gestation

  3. Singleton pregnancy

  4. Agreed to participate in the study and signed on informed consent form.

Exclusion Criteria:
  1. Known ischemic heart disease or angina pectoris

  2. Active smoker

  3. Dyslipidemia, chronic hypertension. Renal disease, diabetes mellitus (gestational or pregestational)

  4. Active treatment with anti-hypertensive medication, anti-aggregation medication or lipid lowering agents.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rabin medical center Petah Tiqwa Israel 49100

Sponsors and Collaborators

  • Rabin Medical Center

Investigators

  • Principal Investigator: Liran Hiersch, Rabin Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Liran hiersch, MD, Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT02334839
Other Study ID Numbers:
  • 0206-14
First Posted:
Jan 8, 2015
Last Update Posted:
Jan 8, 2015
Last Verified:
Jan 1, 2015
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 8, 2015